Zhengye Biotechnology Holding Ltd (ZYBT) — payout ratio, three ways
Fiscal year ending 2024-12-31 · sector Health care · payout ratios computed from SEC filings, not taken from a data vendor.
| Basis | Payout | Why it differs |
|---|---|---|
| GAAP earnings | 160.2% | The figure most screeners publish. |
| Operating cash flow | 39.0% | Before capital spending, so it understates the payout that free cash flow shows. |
| Free cash flow | 58.3% | What is left after maintaining the business. |
Spread between highest and lowest: 121 percentage points. Same filings, different denominators.
Coverage rating 40 / 100 — Tight. ? Peer standing 14/50Direction 15/30Stability 10/20
The arithmetic
- GAAP earnings — dividends declared per share $0.05 ÷ diluted EPS $0.03
- Operating cash flow — dividends paid $2.2m ÷ operating cash flow $5.6m
- Free cash flow — dividends paid $2.2m ÷ (operating cash flow $5.6m − capex $1.9m)
Where the figures came from
- 20-F filed 2025-07-03 · accession
0001213900-25-061202 - 20-F filed 2026-04-28 · accession
0001213900-26-048584
Every one is public at sec.gov and free to check. That is the point — you should not have to take my word for any of it.
Caveats on this company
- DPS derived from dividends paid ($0.05); no per-share tag filed
Computed by an open pipeline reading SEC XBRL directly. If any number here looks wrong to you, tell me — that is more useful to me than agreement.